Article Text

Download PDFPDF
COVID-19 infection in Crohn’s disease under treatment with adalimumab
  1. Antonio Tursi1,
  2. Gioacchino Angarano2,
  3. Laura Monno2,
  4. Annalisa Saracino2,
  5. Fabio Signorile2,
  6. Aurelia Ricciardi2,
  7. Alfredo Papa3
  1. 1 Gastroenterology Service, Azienda Sanitaria Locale Barletta Andria Trani, Andria, Puglia, Italy
  2. 2 Division of Infectious Diseases, Bari University Hospital, University of Bari, Bari, Puglia, Italy
  3. 3 Division of Internal Medicine and Gastroenterology, Complesso Integrato “Columbus”, Catholic University of the Sacred Heart Faculty of Medicine and Surgery, Roma, Lazio, Italy
  1. Correspondence to Professor Antonio Tursi, Gastroenterology Service, Azienda Sanitaria Locale Barletta Andria Trani, 76123 Andria BT, Italy; antotursi{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Jin et al described recently 74 cases of people having COVID-19 and experiencing gastrointestinal symptoms.1 In Italy, we are managing a dramatically increasing number of people infected with severe acute respiratory syndrome corona virus 2, the virus causing COVID-19.2 3 Despite the Italian Government has implemented extraordinary measures to restrict viral spread, including significant decrease of air and train traffic within the country, cases are increasing (>75 000 people until 26 March 2020) also in other regions than Lombardy, which is the main Italian region affected from COVID-19 (>35 000 people until 26 March 2020).4 This means that a lot of people under immunosuppressive-immunomodulating therapies could be infected by this virus, and that the immunosuppressive status could influence both the status of the basic disease and both the course of pulmonary disease.

A 30-year-old male was admitted on emergency department of the Bari University Hospital, Puglia Region, Southern Italy, on 12 March 2020 (with a low number of cases until that date) due to sudden occurrence …

View Full Text


  • Contributors Acquisition, analysis and interpretation of data: AT, GA, LM, AS, FS, AR and AP; drafting the work or revising it critically for important intellectual content: AT and AP; final approval of the version published, agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: AT, GA, LM, AS, FS, AR and AP.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Obtained.

  • Provenance and peer review Not commissioned; internally peer reviewed.